evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

83 questions · 86 findings · 9 reviews · Gut

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 11 · 12.8%GRADE not reported 0 · 0%Very low 33 · 38.4%Low 20 · 23.3%Moderate 20 · 23.3%High 2 · 2.3%

Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues

Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline)

It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes loss of clinical response (at 22 weeks, less than 100 points in CDAI… compared with intravenous CT‐P13 and purine analogues (very low certainty).

1 finding from 1 review

Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues

Withdrawals due to adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)

It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes withdrawal due to adverse events (at 30 weeks) compared with intravenous CT‐P13 and purine analogues (very low certainty).

1 finding from 1 review